Intensive peri-operative use of factor VIII and the missense mutation Arg593Cys are risk factors for factor VIII inhibitors in mild and moderate hemophilia A

C.L. Eckhardt, L.A. Menke, C.H. Van Ommen, J.H. Van Der Lee, R.B. Geskus, P.W. Kamphuisen, M. Peters, K. Fijnvandraat

Research output: Contribution to journalArticleAcademicpeer-review


Background: A severe and challenging complication in the treatment of hemophilia A is the development of factor VIII (FVIII) inhibiting antibodies. Inhibitors aggravate bleeding complications, disabilities and costs. The etiology of inhibitor development is incompletely understood. In a large cohort study in patients with mild or moderate hemophilia A (MHA), we evaluated the role of genotype and intensive FVIII exposure in inhibitor development. Methods: Longitudinal clinical data from 138 MHA patients were retrospectively collected from 1980 to 2008 and analyzed by multivar- iate analysis. Results: Genotyping demonstrated the Arg593Cys missense mutation in 52 (38%) patients, while the remaining 86 patients had 26 other missense mutations. Sixty-three (46%) patients underwent a period of intensive FVIII exposure, in 41 of them for surgery. Ten patients (7%) developed inhibitors, eight of them carrying the Arg593Cys mutation. The Arg593Cys mutation resulted in a threefold increased risk of developing inhibitors (RR 3.1, 95%CI 1.05-9.3).The other two inhibitor patients had newly detected mutations Pro1761Gln and Glu2228Asp. In seven patients the inhibitor occurred within three months after intensive peri-operative use of FVIII concentrates (RR124, 95%CI 66-232). Conclusion: This is the first cohort study in patients with MHA demonstrating that both Arg593Cys genotype and intensive peri-operative use of FVIII concentrates are associated with a high risk for inhibitor development. Limitation of intensive FVIII exposure or use of des- mopressin should be considered in MHA whenever possible.
Original languageEnglish
Pages (from-to)522
Number of pages1
JournalJournal of Thrombosis and Haemostasis
Issue numberS2
Publication statusPublished - Jul-2009
Externally publishedYes


  • blood clotting factor 8
  • blood clotting factor 8 inhibitor
  • antibody
  • hemostasis
  • hemophilia A
  • missense mutation
  • thrombosis
  • risk factor
  • society
  • patient
  • exposure
  • mutation
  • genotype
  • cohort analysis
  • risk
  • etiology
  • clinical study
  • disability
  • bleeding
  • surgery

Cite this